Audebert 1997.

Study characteristics
Methods	Trial design: Open, multi‐centre, central randomised study
Participants	Participants: 120 eligible women; 71 were randomised; 55 were analysed  Mean age: 31 ± 5.9 years  Inclusion criteria:  Laparoscopically diagnosed endometriosis  Symptomatic  Recurrence of endometriosis after surgery  Over 18 years old  No other hormone therapy except insulin  Exclusion criteria:  Amenorrhoea  Patient having had hysterectomy  Pregnant women  Serious illness e.g. liver disease  Setting: France  Timing: January 1989 to February 1991
Interventions	Leuprorelin 3.75 mg SC depot every 28 days for 24 weeks (n = 33)  versus  Danazol 600‐800 mg PO daily for 24 weeks (n = 22)
Outcomes	Relief of overall pain: dysmenorrhoea, dyspareunia, pelvic pain, induration and pelvic tenderness  rAFS score  Adverse effects
Notes	Intention‐to‐treat analysis: yes Sample size calculation: not stated Funding: not stated Note previous version: Could not use data unless mean and SD specified; author contacted. Author replied that study was sponsored by a pharmaceutical company who hold the raw data. He is attempting to locate a contact for further information.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	"Central randomisation". No further details of method used to generate the randomisation sequence were provided.
Allocation concealment (selection bias)	Unclear risk	No details of method used to conceal allocation were provided.
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Open‐label study. No details provided of blinding of participants or personnel
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	No mention of blinding of outcome assessors
Incomplete outcome data (attrition bias) All outcomes	Low risk	Sufficient reporting of attrition:  Refused 2nd laparoscopy n = 1 (leuprolide acetate)  Lost to follow‐up n = 2 (leuprolide acetate) and n = 9 (danazol)  Progression of disease n = 2 (danazol)  Not meeting protocol n = 1 (danazol)  Other n = 1 (danazol)
Selective reporting (reporting bias)	Low risk	The study protocol was not available but it was clear that the published reports included all expected outcomes, including those that were prespecified.
Other bias	Low risk	No other risk of bias detected